Pharma Partnerships: Building Global Success

Why strategic alignment, local market intelligence, and trust are essential to long-term success
in pharmaceutical business development.

By Simone Grisi | Head of Business Development & Partnering, NTC Pharma

The pharmaceutical industry is evolving in an environment shaped by increasingly complex healthcare
needs, changing regulatory expectations, and growing pressure to deliver sustainable commercial
results. For companies seeking international growth, identifying an attractive product or securing a
licensing agreement is only the beginning.
Across Europe, the Middle East, and Asia, market opportunities can appear similar on paper while
requiring very different approaches in practice. The challenge for business development leaders is to
connect commercial ambition with local market realities, and to build partnerships capable of delivering
value well beyond the signing of a contract.

From Transactions to Strategic Partnerships

Pharmaceutical business development is sometimes viewed primarily through the lens of transactions:
identifying an opportunity, evaluating its potential, negotiating terms, and closing a deal. Each step
matters, but none guarantees success on its own.
Whether an organization is bringing external products into its portfolio or expanding the international
reach of its own assets, the fundamental questions are similar. Do the partners share compatible
objectives? Can they contribute the capabilities and resources required? Are expectations realistic,
responsibilities clear, and incentives aligned?
A well-structured agreement establishes the framework. Sustainable performance depends on what
happens afterwards: regulatory progress, supply reliability, market access, commercial execution, and
the ability to respond constructively when circumstances change.
The value of a partnership should therefore be assessed not only by its contractual terms, but by its
capacity to produce meaningful outcomes over time.

Understanding Markets, Not Just Geographies

International expansion requires more than geographic coverage. It demands an understanding of how
healthcare systems, regulatory pathways, procurement models, competition, and commercial practices
differ across individual markets.
This is particularly relevant in the Gulf Cooperation Council. Saudi Arabia and the United Arab Emirates
are both important pharmaceutical markets, yet their healthcare priorities, business ecosystems, and routes to market are not interchangeable. The same principle applies across the wider GCC, as well as
in Central and Eastern Europe, the DACH region, North Africa, and Asian markets.
A strategy that succeeds in one country may require substantial adaptation elsewhere. Before
committing to an opportunity, companies need to assess the therapeutic fit, commercial potential,
regulatory feasibility, competitive landscape, and the capabilities of potential partners.
The strongest international strategies combine a consistent long-term vision with the flexibility to make
informed decisions at local level.

The Human Side of Business Development

Market intelligence, financial modelling, and portfolio analysis are indispensable. Yet even a compelling
business case can fail if the organizations involved cannot work effectively together.
Working across different international markets has taught me that successful business development is
rarely about finding the perfect opportunity on paper. It is about understanding whether two
organizations have the strategic alignment, operational capabilities, and mutual commitment required to
turn that opportunity into a sustainable business. This is where experience, cultural awareness, and the
ability to build trust make the difference.
Trust is built through consistency, transparency, realistic commitments, and the willingness to address
difficult issues openly. In cross-border partnerships, understanding a counterpart’s priorities and
decision-making context is often as important as understanding the commercial proposal itself.
Patience and sound judgement are equally essential. Not every promising discussion should become an
agreement, and not every agreement will achieve its initial expectations. Knowing when to proceed,
adapt, or walk away is part of responsible business development leadership.
Trust is not separate from performance. It enables the cooperation and problem-solving that long-term
performance requires.

Creating Value Through Execution

Licensing and partnership agreements bring together multiple functions whose priorities must remain
aligned. Business development, regulatory affairs, supply chain, quality, finance, market access, and
commercial teams all contribute to the outcome.
An attractive opportunity can lose value when responsibilities are unclear, timelines are unrealistic, or
teams work in isolation. Conversely, disciplined implementation can strengthen a partnership even
when market conditions become more challenging than expected.
This requires business development professionals to look beyond negotiation and understand how
contractual commitments translate into operational plans, measurable milestones, and commercial
decisions.
Negotiation establishes the foundation; coordinated execution ultimately determines the partnership’s
success.

Aligning Portfolio Strategy With Healthcare Needs

Long-term growth in pharmaceuticals depends on more than expanding the number of products or
markets served. It requires thoughtful portfolio choices that balance commercial opportunity with
healthcare relevance.
A product that appears attractive in isolation may create greater value when it complements an existing
therapeutic portfolio, addresses a defined patient need, or strengthens a partner’s capabilities in a
particular market. Equally, a commercially promising asset may not be the right fit if regulatory
requirements, competitive conditions, or execution resources are misaligned.
The role of business development is therefore to connect external opportunities with strategic priorities
while remaining realistic about what each organization can deliver. The objective is not simply to pursue
more deals, but to pursue the right partnerships.

Looking Ahead: Partnership as a Competitive Advantage

As pharmaceutical markets evolve, companies will continue to seek new technologies, products,
capabilities, and routes to patients. The organizations best positioned to succeed will be those that
combine rigorous opportunity assessment with a genuine commitment to collaboration.
For business development leaders, this means remaining curious, questioning assumptions,
understanding different perspectives, and recognizing that long-term relationships require continual
attention rather than a single successful negotiation.
My professional philosophy is straightforward: business development is not simply about connecting
products with markets. It is about aligning strategies, capabilities, and people to create sustainable
value that neither partner could achieve alone.
Ultimately, the strongest pharmaceutical partnerships are not defined by the deal that starts them, but
by the shared progress they make possible.

About the Author

Simone Grisi is an international pharmaceutical business development executive with over 20 years of
experience spanning commercial leadership, strategic portfolio development, licensing, and cross-border
partnerships. His career has included responsibilities across European, Middle Eastern, and Asian markets,
combining commercial strategy, international negotiation, and relationship-driven partnership development. He
currently serves as Head of Business Development & Partnering at NTC Pharma. His professional approach
focuses on strategic alignment, mutual trust, and creating sustainable value through international
collaboration.